Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Aerovate Therapeutics is raising $75,818,727.00 in new funding. Sources indicate as part of senior management President, Benjamin Dake played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aerovate Therapeutics

Aerovate is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s lead program is a potentially disease modifying drug for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of imatinib that delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects.

To learn more about Aerovate Therapeutics, visit http://www.aerovatetx.com/

Contact:
Benjamin Dake, President
617-778-2494
https://www.linkedin.com/in/ben-dake-632b4425/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved